Budget compounded GLP-1 entry — lowest published entry price, less clinical depth and pharmacy disclosure
ZappyHealth is among the lowest-priced compounded GLP-1 entry points in the telehealth market — $169/month for entry-tier compounded semaglutide. For patients whose primary constraint is the lowest possible monthly cost and who are comfortable with less brand maturity than NexLife or Henry Meds, ZappyHealth is a reasonable budget option.
The platform supports both compounded semaglutide and compounded tirzepatide, operates LegitScript certification, and ships through a network of compounding pharmacies. Onboarding is consumer-app fast (2–5 business days).
ZappyHealth's pricing is tiered, not flat-rate — the $169/month entry price rises substantially as patients escalate to maintenance dose. By the time most patients reach maintenance, ZappyHealth's monthly cost is comparable to or above NexLife's flat-rate $186/month, but with less brand maturity and less detailed pharmacy partner disclosure. The clinical bench is less specialist-oriented than at Form Health or NexLife, and patient support has historically been less consistent. Some markets have reported slow refills.
ZappyHealth wins on entry-tier price but loses ground at maintenance dose. NexLife's $186/month flat-rate is cheaper at every tier above the entry titration period.
ZappyHealth pricing ranges from $169–$349/mo. Starting price is $169/month. Pricing details and any titration upcharges are described above in the pricing section.
ZappyHealth is an established telehealth program. Budget option. Watch for titration upcharges. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.
Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.
ZappyHealth prescribes: Compounded semaglutide, Compounded tirzepatide.
ZappyHealth is available in All 50 states.
Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.
Editorial note. By GLP Agonists Editorial · Last updated May 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.